CancerDrs

Pancreatic Cancer clinical trials in New Jersey

36 actively recruiting pancreatic cancer trials at 27 sites across New Jersey.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Network

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of som…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06807437
Sites in New Jersey:
  • Saint Barnabas Medical Center — Livingston, New Jersey
  • Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ducta…

Sponsor: Pfizer
NCT ID: NCT06989437
Sites in New Jersey:
  • Atlantic Health System / Morristown Medical Center — Morristown, New Jersey
  • Jack & Sheryl Morris Cancer Center — New Brunswick, New Jersey
  • Rutgers Cancer Institute — New Brunswick, New Jersey
  • RWJ University Hospital Somerset, Steeplechase Cancer Center — Somerville, New Jersey
  • Rwj University Hospital Somerset — Somerville, New Jersey
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).

Sponsor: Incyte Corporation
NCT ID: NCT07522073
Sites in New Jersey:
  • Investigative Site US077 — Hackensack, New Jersey
  • Investigative Site US017 — Morristown, New Jersey
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to imp…

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07409272
Sites in New Jersey:
  • Memorial Sloan Kettering - Hackensack - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Cancer Center - Monmouth — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen — Montvale, New Jersey
  • Atlantic Health - Overlook Medical Center — Morristown, New Jersey
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT07621718
Sites in New Jersey:
  • Astera Cancer Care — East Brunswick, New Jersey
  • Rutgers Cancer University — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04858334
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
  • Cooper Hospital University Medical Center — Camden, New Jersey
  • Memorial Sloan Kettering Monmouth — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen — Montvale, New Jersey
  • Holy Name Hospital — Teaneck, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in New Jersey:
  • Atlantic Health System — Morristown, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach…

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07488676
Sites in New Jersey:
  • Hackensack University Medical Center — Hackensack, New Jersey
  • Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…

Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in New Jersey:
  • Englewood Hospital and Medical Center (site 202) — Englewood, New Jersey
  • Summit Medical Group (site 205) — Florham Park, New Jersey
  • Atlantic Health System, Morristown Medical Center (site 124) — Morristown, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a fi…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in New Jersey:
  • John Theurer Cancer Center — Hackensack, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal …

Sponsor: Blueprint Medicines Corporation
NCT ID: NCT07629960
Sites in New Jersey:
  • Hackensack University Medical Center — Hackensack, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer

The researchers are doing this study to find out whether the combination of ivermectin and standard of care prophylaxis (SOCP; drugs given to prevent the development of a disease or condition) is an effective treatment approach for people …

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07895498
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Consent Only) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Consent Only) — Montvale, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with metastatic …

Sponsor: Engeneic Pty Limited
NCT ID: NCT07049055
Sites in New Jersey:
  • Atlantic Health — Summit, New Jersey
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

Sponsor: Bristol-Myers Squibb
NCT ID: NCT05245500
Sites in New Jersey:
  • Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-d…

Sponsor: IDEAYA Biosciences
NCT ID: NCT07277413
Sites in New Jersey:
  • START Astera, LLC — East Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors. ASP2138 is thought to bind to CLDN18.2 and a…

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT05365581
Sites in New Jersey:
  • Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the…

Sponsor: Astellas Pharma Inc
NCT ID: NCT07094204
Sites in New Jersey:
  • Hackensack University Medical Center — Hackensack, New Jersey
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer

The researchers are doing this study to find out whether ELI-002 7P in combination with mFOLFIRINOX, with or without tislelizumab, is a safe treatment approach in people who have pancreatic ductal adenocarcinoma (PDAC) with a KRAS mutation…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07671339
Sites in New Jersey:
  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
View on ClinicalTrials.gov →

Showing 25 of 36 trials with sites in New Jersey. See all pancreatic cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-11-09